European Heart Journal Advance Access originally published online on July 18, 2007
European Heart Journal 2007 28(17):2156-2162; doi:10.1093/eurheartj/ehm263
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology
1 Department of Cardiology, UZ Brussel, Brussels, Belgium
2 Department of Nuclear Medicine, UZ Brussel, Brussels, Belgium
3 Department of Pathology, UZ Brussel, Brussels, Belgium
4 In Vivo Cellular and Molecular Imaging Center (ICMIC), Vrije Universiteit Brussel (VUB), Brussels, Belgium
5 Experimental Pathology (EXPA), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium
Received 10 January 2007; revised 18 April 2007; accepted 31 May 2007; online publish-ahead-of-print 18 July 2007.
* Corresponding author. Tel: +32 2 477 6010; fax: +32 2 477 6840. E-mail address: steven_droogmans{at}yahoo.com
Aims: Valvular heart disease (VHD), inducing valvular regurgitation, has been described in carcinoid heart disease and recently in Parkinson’s patients treated with pergolide. The aim of this study was to develop an in vivo model of drug-induced valvulopathy with pergolide in rats.
Methods and results: Thirty male Wistar rats were given daily injections of either pergolide (0.5 mg/kg intraperitoneally) (n = 8), serotonin (20 mg/kg subcutaneously) (n = 8), or the vehicle only (n = 14) for 5 months. At 20 weeks, echocardiography demonstrated the presence of aortic regurgitation (AR) and/or mitral regurgitation (MR) in serotonin (86% AR, P = 0.0001; 57% MR, P = 0.006) and in pergolide animals (67% AR, P = 0.003; 67% MR, P = 0.003) compared with none in placebo. Pulmonary regurgitation (PR) and tricuspid regurgitation (TR) were found in the serotonin (71% PR, P = 0.19; 100% TR, P = 0.06 vs. placebo), pergolide (100% PR, P = 0.014; 83% TR, P = 0.35 vs. placebo), and placebo groups (36% PR; 57% TR). Tricuspid regurgitant area ratio (jet/atrium), however, was more severe in the serotonin [median 26.5 (range 17–42)%; P = 0.02] and pergolide animals [32 (17–39) %; P = 0.03] compared with placebo [12.5 (5–33)%]. We found a good correlation between valvular regurgitation and histologically assessed valvular thickness. Histological examination revealed the presence of diffusely thickened and myxoid aortic, mitral, and tricuspid valves in serotonin and pergolide animals as seen in VHD.
Conclusion: We demonstrated, for the first time, that long-term pergolide administration led to VHD in rats. This small animal model will permit further in vivo investigation of drug-induced valvulopathies.
Key Words: Echocardiography • Pathology • Drugs • Small animals • Valves
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Droogmans, B. Cosyns, and G. Van Camp Pergolide and valvular heart disease: the lower the better? Eur J Echocardiogr, July 18, 2008; (2008) jen202v1. [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Donnelly Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases Toxicol Pathol, February 1, 2008; 36(2): 204 - 217. [Abstract] [Full Text] [PDF]
|
|